Sunday, Sep 21st

Last update02:57:29 PM GMT






You are here: BioMedTech


Bug-busting company secures £500k funding

Dr Michael McArthur, CSO of Procarta BiosystemsA company wrestling with the problem of how to kill harmful bacteria while retaining bacteria beneficial to the body has raised crucial new investment of £500k.

Bold meets bald in business plan competition

The Calvitium Solutions’ winning teamAspiring biotechnology entrepreneurs from the University of Cambridge won the Biotechnology Young Entrepreneurs Scheme (YES) 2012 after a day of tough competition in London.

Vernalis progresses Parkinson's solution

Ian GarlandVernalis plc, the Cambridge UK biotechnology company, has reported successful results from a Receptor Occupancy (RO) study with V81444, its A2A antagonist which has potential applications in Parkinson's disease and other CNS indications.

LondonPharma in bid to cut child malaria deaths

Clive BoolesA Norwich company is close to completing Phase III trials on an under-the-tongue spray which could dramatically reduce child malaria deaths.

Cambridge antibody revolution hits California

Dr Allan BradleyAntibody technology pioneers from Cambridge today took their medical revolution from the UK to California.

Sentinel earns EU blood cancer cash

Stuart Travers of Sentinel Oncology receiving the Network Stars award from Joanna Drake, the EC’s director for SMEs and Entrepreneurship, Enterprise and IndustryA Cambridge UK medical technology business has been honoured by the European Union with an award to celebrate its work researching new treatments for blood cancer.

BioFocus hits UCB collaboration milestone

BioFocus cashes in on allianceBioFocus has received an unspecified development milestone payout under its medicinal chemistry deal with UCB.

Key to rare genetic disorder in children

Dr David Adams, lead author from the Wellcome Trust Sanger InstituteResearchers have defined the gene responsible for a rare developmental disorder in children and hope that follow-on tests could ultimately lead to therapies.

Page 52 of 126